How do patients with secondary progressive multiple sclerosis enrolled in the EXPAND randomized controlled trial compare with those seen in German clinical practice in the NeuroTransData multiple sclerosis registry?

BACKGROUND: In EXPAND (NCT01665144), a phase 3 randomized clinical trial, siponimod reduced disability progression versus placebo in patients with secondary progressive multiple sclerosis (SPMS). AIM: To understand how a real-world population with SPMS relates to that in EXPAND, we conducted a retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Braune, Stefan, Bergmann, Arnfin, Bezlyak, Vladimir, Adlard, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358581/
https://www.ncbi.nlm.nih.gov/pubmed/35958354
http://dx.doi.org/10.1177/11795735221115912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358581/
https://www.ncbi.nlm.nih.gov/pubmed/35958354
http://dx.doi.org/10.1177/11795735221115912

Ejemplares similares